Adverum faces murky future after review turns up deeper safety issues for gene therapy

Jason Mast

Editor

Three months after revealing that a patient lost significant vision in one eye after receiving its experimental gene therapy, Adverum announced it found …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Adverum faces murky future after review turns up deeper safety issues for gene therapy

Jason Mast

Editor

Sign up to read this article for free.

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Ad­verum faces murky fu­ture af­ter re­view turns up deep­er safe­ty is­sues for gene ther­a­py

Jason Mast

Editor

Sign up to read this article for free.

more like this

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Adverum faces murky future after review turns up deeper safety issues for gene therapy

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B